Outset Medicals Revenue Dips, Shares Plunge 11% After Earnings

Outset Medical reported its 2025 Q4 results on Feb 13th, 2026, showing a 2% revenue decline to $28.87 million and a 24% narrower net loss of $19.49 million compared to 2024 Q4. The company highlighted improved operational efficiency and a strengthened balance sheet, with $173 million in cash and investments. CEO Leslie Trigg emphasized a "strong foundation for growth" as the firm prepares to launch its next-gen Tablo platform in Q2 2026.

Revenue

Outset Medical’s total revenue decreased by 2.0% to $28.87 million in 2025 Q4, down from $29.47 million in 2024 Q4. Product revenue totaled $19.9 million, while service and other revenue rose 6% to $9 million. Recurring revenue from Tablo consumables and services, a critical growth driver, fell to $22.5 million compared to $23.7 million in the prior year.

Earnings/Net Income

Outset Medical’s losses widened to $1.07 per share in 2025 Q4 from $0.48 per share in 2024 Q4 (121.6% wider loss). However, the company reduced its net loss to $-19.49 million, a 24.0% improvement from $-25.64 million in 2024 Q4. Despite a 24% reduction in net loss, the per-share loss expansion indicates ongoing challenges in scaling profitability.

Post-Earnings Price Action Review

Following the earnings release, OM shares plunged 11.02% in a single day, compounded by a 24.67% weekly drop and a 33.79% month-to-date decline. A strategy of buying shares post-revenue decline and holding for 30 days yielded a -99.55% return over three years, underperforming the benchmark by 155.07%. The strategy’s Sharpe ratio of -0.70 and 99.74% maximum drawdown underscore its high risk and vulnerability to market downturns.

CEO Commentary

Leslie Trigg, Chair and Chief Executive Officer, emphasized Outset Medical’s “strong foundation for growth” in 2026. She highlighted the company’s $173 million cash balance, 500-basis-point gross margin expansion, and the upcoming launch of the next-gen Tablo platform. Trigg noted progress in streamlining operations, with 8% lower operating expenses year-over-year, and reiterated confidence in the Tablo platform’s potential to transform dialysis care.

Guidance

Outset Medical provided no explicit forward-looking revenue or EPS guidance for 2026. The CEO’s remarks focused on qualitative priorities, including accelerating the Tablo platform rollout, maintaining operational efficiency, and leveraging recurring revenue from consumables to drive long-term profitability.

Additional News

1. FDA Clearance for Next-Gen Tablo Platform: Outset Medical received FDA clearance for its enhanced Tablo system, featuring enterprise-level cybersecurity and connectivity, slated for a Q2 2026 launch.

2. Operational Efficiency Gains: The company reduced 2025 operating expenses by 8% year-over-year, with R&D and sales/marketing costs declining by 35% and 17%, respectively.

3. Cash Flow Improvements: Net cash used in operations dropped to $46 million in 2025 from $116 million in 2024, reflecting better working capital management and cost controls.